89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Fred Baik, MD
Stanford Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford Cancer Institute
San Francisco, California, United States
Andrei Iagaru, MDBenjamin L Franc, MD, MS, MBACarina Aparici, MDChris Holsinger, MDDimitrios Colevas, MDFarshad Moradi, MD, PhDFred Baik, MDGuido Davidzon, MDJagruti Shah, MBBSSaad Khan, MDVasu Divi, MDYu-Jin Lee, MD, MS
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2026
- Primary completion
- 31 Dec 2027
- Completion
- 31 Dec 2027
- Last update posted
- 16 Jul 2025
- Registered enrollment
- 60
- Registry id
- NCT05423197
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.